CCM® Therapy

Impulse Dynamics is determined to improve the lives of people with heart failure and is the developer of the innovative Optimizer® CCM® Therapy delivery system. CCM Therapy is a breakthrough heart failure treatment proven to improve quality of life for heart failure patients. CCM Therapy is specifically designed to improve systolic contraction in an effort to deliver more oxygen-rich blood to the body. CCM Therapy is a safe and effective, minimally invasive treatment option for millions of heart failure patients who otherwise have few or no effective options available to them. Optimizer® is the first and only FDA-approved device in the U.S. or elsewhere for the delivery of CCM Therapy.

Our mission at Impulse Dynamics is to exceed the expectations of patients, clinicians, and caregivers alike by developing and providing cardiac contractility modulation. The company believes in fostering innovation, transparency, and accountability in our relentless efforts to expand global access to the benefits of CCM Therapy.

www.impulsedynamics.com


 

ESC-HF 2021 - Electrical Therapy for the Treatment of Heart Failure – Cardiac Contractility Modulation

0 views
August 2, 2021
This video is a lecture from the ESC- HF session that virtually took place. Dr. Nir Uriel and Prof. Andrew Coats moderate this session titled Electrical Therapy for the Treatment of Heart Failure - Cardiac Contractility Modulation. This is a lecture from that session where Dr. Javed Butler discusses the ongoing research efforts with cardiac contractility modulation including the HFpEF population as well as the clinical history and evidence that supports the clinical evidence that supports the use of CCM in the management of Heart Failure Patients.

  • October 26, 2021 - U.S. Food and Drug Administration approved a modification of labeling for the Optimizer® Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement as of 10/26/2021. Please note that this presentation was done prior to this FDA update.
Comments 0
Login to view comments. Click here to Login